The AURA3 trial randomized EGFR-mutant NSCLC patients who progressed to first-generation EGFR-TKIs, due to the acquired EGFR-T790M mutation, to receive osimertinib or platinum-pemetrexed chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.